within Pharmacolibrary.Drugs.ATC.R;

model R03BB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.07,
    Cl             = 7.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oxitropium bromide is an anticholinergic bronchodilator used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It acts as a muscarinic receptor antagonist, leading to relaxation of bronchial smooth muscle. Oxitropium bromide was formerly approved for use as an inhaled therapy in several countries, but is not widely used or available in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimates in adults based on available reviews and analogies with related quaternary anticholinergic inhaled drugs. No direct referenced scientific publication quantifying specific PK parameters for oxitropium bromide in humans.</p><h4>References</h4><ol><li><p>Holgate, ST (1987). Anticholinergics in acute bronchial asthma. <i>Postgraduate medical journal</i> 63 Suppl 1(743) 35–39. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2962072/&quot;>https://pubmed.ncbi.nlm.nih.gov/2962072</a></p></li><li><p>Ensing, K, et al., &amp; Cornelissen, PJ (1989). Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. <i>European journal of clinical pharmacology</i> 37(5) 507–512. DOI:<a href=&quot;https://doi.org/10.1007/BF00558132&quot;>10.1007/BF00558132</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2598990/&quot;>https://pubmed.ncbi.nlm.nih.gov/2598990</a></p></li><li><p>Restrepo, RD (2007). Use of inhaled anticholinergic agents in obstructive airway disease. <i>Respiratory care</i> 52(7) 833–851. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17594728/&quot;>https://pubmed.ncbi.nlm.nih.gov/17594728</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03BB02;
